PE20090479A1 - Composicion farmaceutica que comprende la combinacion de un agente anticonvulsivante y un agente benzodiazepinico, indicada para el control y tratamiento de trastornos convulsivos y sindromes epilepticos - Google Patents
Composicion farmaceutica que comprende la combinacion de un agente anticonvulsivante y un agente benzodiazepinico, indicada para el control y tratamiento de trastornos convulsivos y sindromes epilepticosInfo
- Publication number
- PE20090479A1 PE20090479A1 PE2008001182A PE2008001182A PE20090479A1 PE 20090479 A1 PE20090479 A1 PE 20090479A1 PE 2008001182 A PE2008001182 A PE 2008001182A PE 2008001182 A PE2008001182 A PE 2008001182A PE 20090479 A1 PE20090479 A1 PE 20090479A1
- Authority
- PE
- Peru
- Prior art keywords
- agent
- confusion
- treatment
- pharmaceutical composition
- combination
- Prior art date
Links
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 title abstract 2
- 208000002877 Epileptic Syndromes Diseases 0.000 title abstract 2
- 229940049706 benzodiazepine Drugs 0.000 title abstract 2
- 206010015037 epilepsy Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000002775 capsule Substances 0.000 abstract 1
- 229960003120 clonazepam Drugs 0.000 abstract 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 abstract 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 abstract 1
- 229960001848 lamotrigine Drugs 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE: A) UN AGENTE ANTICONVULSIVANTE TAL COMO LAMOTRIGINA QUE SE ENCUENTRA EN UNA CANTIDAD DE 25MG A 500MG EN LA COMPOSICION; Y B) UN AGENTE BENZODIAZEPINICO TAL COMO CLONAZEPAM QUE SE ENCUENTRA EN UNA CANTIDAD DE 0.5MG A 20MG EN LA COMPOSICION. DICHA COMPOSICION ES UNA COMBINACION SINERGICA UTIL EN EL TRATAMIENTO DE SINDROMES EPILEPTICOS, TRASTORNOS CONVULSIVOS Y FORMULADA EN UNA SOLA UNIDAD DE DOSIFICACION PARA SU ADMINISTRACION POR VIA ORAL EN FORMA DE CAPSULAS O TABLETAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2007008644A MX2007008644A (es) | 2007-07-16 | 2007-07-16 | Composicion farmaceutica que comprende la combinacion de un agente anticonvulsivante y un agente benzodiazepinico, indicada para el control y tratamiento de trastornos convulsivos y sindromes epilepticos. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20090479A1 true PE20090479A1 (es) | 2009-05-06 |
Family
ID=40259825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008001182A PE20090479A1 (es) | 2007-07-16 | 2008-07-15 | Composicion farmaceutica que comprende la combinacion de un agente anticonvulsivante y un agente benzodiazepinico, indicada para el control y tratamiento de trastornos convulsivos y sindromes epilepticos |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2179735A4 (es) |
| AR (1) | AR067861A1 (es) |
| BR (1) | BRPI0813529A2 (es) |
| CL (1) | CL2008002116A1 (es) |
| CO (1) | CO6290647A2 (es) |
| EC (1) | ECSP109877A (es) |
| MX (1) | MX2007008644A (es) |
| PE (1) | PE20090479A1 (es) |
| UY (1) | UY31230A1 (es) |
| WO (1) | WO2009011561A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114369061B (zh) * | 2022-01-28 | 2024-05-03 | 济南同路医药科技发展有限公司 | 一种氯硝西泮有关物质b的制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060128995A (ko) * | 2004-01-13 | 2006-12-14 | 듀크 유니버시티 | 체중감량에 영향을 미치는 항경련제와 항정신병 약물의조성물 |
-
2007
- 2007-07-16 MX MX2007008644A patent/MX2007008644A/es not_active Application Discontinuation
-
2008
- 2008-07-15 PE PE2008001182A patent/PE20090479A1/es not_active Application Discontinuation
- 2008-07-16 AR ARP080103047A patent/AR067861A1/es not_active Application Discontinuation
- 2008-07-16 BR BRPI0813529-0A patent/BRPI0813529A2/pt not_active IP Right Cessation
- 2008-07-16 EP EP08778983A patent/EP2179735A4/en not_active Withdrawn
- 2008-07-16 WO PCT/MX2008/000093 patent/WO2009011561A1/es not_active Ceased
- 2008-07-16 UY UY31230A patent/UY31230A1/es not_active Application Discontinuation
- 2008-07-17 CL CL2008002116A patent/CL2008002116A1/es unknown
-
2010
- 2010-01-14 CO CO10003243A patent/CO6290647A2/es not_active Application Discontinuation
- 2010-01-15 EC EC2010009877A patent/ECSP109877A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2179735A4 (en) | 2010-11-17 |
| MX2007008644A (es) | 2009-02-18 |
| CO6290647A2 (es) | 2011-06-20 |
| ECSP109877A (es) | 2010-02-26 |
| AR067861A1 (es) | 2009-10-28 |
| UY31230A1 (es) | 2009-01-05 |
| CL2008002116A1 (es) | 2009-03-20 |
| EP2179735A1 (en) | 2010-04-28 |
| BRPI0813529A2 (pt) | 2015-07-14 |
| WO2009011561A1 (es) | 2009-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP10010224A (es) | Formulaciones líquidas de hormona luteinizante (lh). | |
| CO6400186A2 (es) | Tabletas de acetato de ulipristal | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| EA201690107A1 (ru) | Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе | |
| MX2019002265A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| CO6690805A2 (es) | 6-amino-nicotinamidas sustituidas como modulares de kcnq2/3 | |
| ECSP088239A (es) | Composición de liberación de fármaco sostenida | |
| PA8780201A1 (es) | Derivados de pirasol sustituidos con heteroaril utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis | |
| CL2011002858A1 (es) | Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor. | |
| AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
| CL2007001724A1 (es) | Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1 | |
| CR11418A (es) | Trans-clomifeno para el sindrome metabolico | |
| CL2008000610A1 (es) | Composicion en forma de dosificacion transdermica o transmucosa que comprende una relacion en peso de buprenorfina a naloxona entre 2,1:1 y 8:1, util para el tratamiento del dolor. | |
| JP2016530291A5 (es) | ||
| MX2010001243A (es) | Composicion anti-inflamatoria. | |
| CL2008000674A1 (es) | Compuestos derivados de 1,4-diarilacetidinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto como agente reductor de los niveles de colesterol, para el tratamiento de trastornos del metabolismo lipidico, aterosclerosis | |
| EA200802104A1 (ru) | Применение композиций, содержащих антагонисты каппа-опиоидных рецепторов, для лечения диссоциативных расстройств | |
| AR083095A1 (es) | Cocristal de aprepitant l-prolina y composicion farmaceutica | |
| PE20090524A1 (es) | Composicion farmaceutica que comprende la combinacion de una triazolobenzodiazepina y un agente inhibidor selectivo de la recaptura de serotonina | |
| ECSP099734A (es) | Composición farmaceutica que comprende la combinación de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante | |
| PE20090479A1 (es) | Composicion farmaceutica que comprende la combinacion de un agente anticonvulsivante y un agente benzodiazepinico, indicada para el control y tratamiento de trastornos convulsivos y sindromes epilepticos | |
| GT201000064A (es) | Formulaciones galénicas de alisquireno | |
| AR073086A1 (es) | Composicion farmaceutica para el tratamiento de un trastorno de ansiedad que comprende exo-7-(8-h-8-aza-biciclo(3,2,1)oct-3-iloxi)-cromen-2-ona, uso y equipo | |
| AR080541A1 (es) | Tratamiento para la endometriosis | |
| CR10912A (es) | Preparacion framaceutica para reducir la endometriosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |